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Background: Attribute selection represents an important step in the development of 
 discrete-choice experiments (DCEs), but is often poorly reported. In some situations, the number 
of attributes identified may exceed what one may find possible to pilot in a DCE. Hence, there 
is a need to gain insight into methods to select attributes in order to construct the final list of 
attributes. This study aims to test the feasibility of using the nominal group technique (NGT) 
to select attributes for DCEs.
Methods: Patient group discussions (4–8 participants) were convened to prioritize a list of 
12 potentially important attributes for osteoporosis drug therapy. The NGT consisted of three 
steps: an individual ranking of the 12 attributes by importance from 1 to 12, a group discussion 
on each of the attributes, including a group review of the aggregate score of the initial rankings, 
and a second ranking task of the same attributes.
Results: Twenty-six osteoporotic patients participated in five NGT sessions. Most (80%) of the 
patients changed their ranking after the discussion. However, the average initial and final  ranking 
did not differ markedly. In the final ranking, the most important medication attributes were 
 effectiveness, side effects, and frequency and mode of administration. Some (15%) of the patients 
did not correctly rank from 1 to 12, and the order of attributes did play a role in the ranking.
Conclusion: The NGT is feasible for selecting attributes for DCEs. Although in the context of 
this study, the NGT session had little impact on prioritizing attributes, this approach is rigorous, 
transparent, and improves the face validity of DCEs. Additional research in other contexts 
(different decisional problems or different diseases) is needed to determine the added value of 
the NGT session, to assess the optimal ranking/rating method with control of ordering effects, 
and to compare the attributes selected with the different approaches.
Keywords: discrete choice experiment, nominal group technique, patient preference, medication 
attributes, osteoporosis
Introduction
Over the last decade, discrete choice experiments (DCEs) have been increasingly used 
to elicit preferences for health care.1–3 Identification and selection of attributes are 
fundamentally important to obtain valuable results4,5 but are often poorly reported.5 
Methods used to identify attributes include literature review, discussion with experts, 
professional recommendations, surveys, indepth interviews, focus groups, and repertory 
grid techniques.5,6 This first stage would generate a list of potential attributes for 
inclusion. In some situations, the number of attributes identified may exceed what one 
may find possible to pilot in a DCE. When the number of attributes may need to be 
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Good Research Practices for Conjoint Analysis Task Force 
has suggested that rating and/or ranking exercises may be 
beneficial in assessing the importance of attributes in order 
to construct the final list of attributes to be included.1 Some 
of the earlier techniques can again be used (eg, focus groups 
and interviews), but with a different objective from that in 
the identification stage.
The nominal group technique (NGT) seems particularly 
suitable for the “second” stage in which attributes are selected 
from the list by ranking them. The NGT is a structured, 
multistep, facilitated group meeting technique used to elicit 
and prioritize responses to a specific question.7 This method 
has been shown to be feasible and reliable for prioritizing 
health and health care research/problems,8,9 but has never 
been investigated to select attributes for DCEs.
Therefore, this study was designed to assess use of the 
NGT to prioritize attributes for inclusion in DCEs. The study 
context is preferences for osteoporosis medications among adult 
patients. With the recent introduction of new therapies, conduct-
ing a DCE would be useful to understand patient preferences for 
these treatments, especially in view of the poor adherence with 
drug treatment in osteoporosis, but a DCE requires a rigorous 
and transparent approach to select  attributes, given that many 
potential attributes have been identified in surveys10,11 and prior 
DCEs.12–14 While the results provide insight into preferences 
regarding the attributes of medications for osteoporosis, the 
primary objective of this paper was to test the feasibility and 
usefulness of the NGT to select attributes for DCEs. A second-
ary objective was to assess the influence of attribute ranking 
order on the selection of attributes.
Materials and methods
Patients
Five patient group discussions (consisting of 4–8 partici-
pants per NGT session) were conducted in June 2011 in The 
Netherlands and in Belgium to prioritize patient prefer-
ences for medication attributes. Patients were recruited 
during outpatient clinics or by telephone. Participants were 
considered eligible for inclusion in the study if they were 
diagnosed with osteoporosis or had a recent fracture that 
required osteoporosis medication during at least a period of 
their osteoporosis history. They were selected to represent 
the full clinical spectrum of age, educational level, history 
of osteoporosis (primary or secondary), and osteoporosis 
medication (switched, stopped, experienced side effects). The 
ethics committee of Maastricht University Medical Center 
approved the study and all patients received an information 
letter before participating and provided written consent.
Identification of candidate attributes
Fourteen potentially important attributes of osteoporosis 
drug therapy were established from a literature review10–15 
and discussion with experts. Two attributes, ie, treatment 
duration and drug interactions, were not included in the final 
list because these attributes did not meet the important condi-
tions of attributes for DCEs, such as being capable of being 
traded and being policy relevant.4,5 Indeed, treatment duration 
does not differ between first-line osteoporosis therapies, so 
is not relevant to policy, and drug interactions are very rare 
for all drugs used to treat osteoporosis.16 The final list of 
12 attributes (Table 1) was approved by the working group, 
which included project investigators (rheumatologists, DCE 
experts), advisors, and a patient. A different ordering to pres-
ent and discuss the attributes was used in each of the groups. 
Attributes were randomly divided into five sets (attributes 
1–3, 4–6, 7–8, 9–10, and 10–11), and each of the five discus-
sion groups received a different ordering of these sets.
Nominal group process
The NGT process consisted of three steps. After being 
informed about the purpose of the study (“to determine the 
most important characteristics for drug therapy in osteopo-
rosis from the perspective of the patients”) and being given a 
brief description of the NGT process and its attributes, each 
participant was asked to rank the list of attributes by impor-
tance from 1 (the most important) to 12 (the least important) 
on a worksheet. Patients also had the opportunity to include 
any missing attribute. In comparison with a traditional NGT,17 
and because many attributes were already identified in the 
literature, we did not include a first stage of silent generation 
of ideas whereby participants are asked to write down all 
ideas (attributes in this context) about a question.
During a second step (discussion and sharing ideas), 
a group discussion on each of the attributes was held, and 
Table 1 List of potentially important attributes
 1. Efficacy (effect) in reducing the risk of future fractures (decreasing by 
between 20%–75% of the risk of future fractures)
 2. Side-effects (mild and common; serious and rare)
 3. Biological mechanism of action (bone resorption or bone formation)
 4. Frequency of administration (daily, weekly, monthly, yearly, etc)
 5. Mode of administration (oral tablet, subcutaneous, intravenous, etc)
 6. Place of administration (at home, doctor’s office, hospital, etc)
 7. Same drug during the treatment period (or sequential treatment)
 8. Mono therapy vs combination therapy (one or two pills)
 9. Out-of-pocket cost (personal contribution)
10. Cost for the society (other health care costs than patient contribution) 
11. Time on market (recently vs 10 years)
12. Branded or generic specification
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included a group review of the aggregate score of the initial 
rankings. In the final phase, participants had the opportunity 
to reconsider their initial ranking in light of other participants’ 
views. They were under no pressure to achieve consensus, and 
all ratings were again made privately. The discussions were 
facilitated by a medical trainee in rheumatology, observed by 
a moderator, and tape-recorded. The facilitator tried to ensure 
that all participants were given an opportunity to contribute. 
NGT sessions were conducted until the rank order of the most 
important attributes did not change any further.
For each of the five groups, the individual rankings were 
summed across participants to derive the rank order at the group 
level. Some recoding was performed for a few patients who 
assigned the same number to different attributes. Any change 
between the initial and final round was examined to indicate the 
impact of the NGT on ranking. This analysis was carried out 
at the group level and at the individual level by examining the 
number of attributes changed by responders and the average of 
the (absolute) change between rankings of attributes.
Selection of final attributes
Selection of attributes for the DCE was based on group rank-
ing and NGT discussions, followed by discussion among the 
experts, who decided on the number of attributes that should 
be included. The NGT sessions were particularly useful to 
determine the cutoff level beyond which inclusion as an 
attribute on the final ranking list should be stopped. The final 
list of attributes was further approved by the working group. 
No fixed threshold number was used to select attributes for 
inclusion, although recent reviews have reported that most 
DCEs used a number of attributes between 4 and 7.18,19
Results
Study sample
After five group discussions (two in The Netherlands and 
three in Belgium), the rank order of the attributes did not 
change any further, and no additional groups were invited. 
The final sample consisted of 26 patients with osteoporosis. 
As seen in Table 2, the patients represented the full clinical 
spectrum of age, educational level, osteoporosis diagnosis, 
fracture history, and treatment. Patient characteristics did not 
markedly differ between groups.
Final ranking of most important 
attributes
Figure 1 presents the five most important attributes in the 
different patient groups. Drug effectiveness was the most 
important medication attribute, followed by side effects, 
frequency of administration, and mode of administration, 
respectively. While out-of-pocket costs, time on market, 
place of administration (eg, hospital or home), and need for 
sequential treatment were of some relevance, costs to society, 
mode of action, combination treatment, and brand/generic 
specification did not reach the top three most important 
attributes in any of the groups.
Effect of NGT on rank order
Twenty of the 25 patients (80%) who provided an initial 
and final ranking changed their ranking after the discussion. 
However, the average initial and final ranking did not differ 
importantly, with two exceptions (Table 3). The importance 
of mode of action was reduced after discussion (from posi-
tion 5 to position 8), while the out-of-pocket costs increased 
from position 10 to 5 because, in two Belgian groups, the 
importance of this attribute increased by 3 and 4 places, 
respectively, after the discussion. Mode of action was con-
sidered by most patients as a way of improving effective-
ness and reducing fractures, although drug effectiveness is 
largely independent of the biological mechanism of drugs. 
This explanation was provided during the NGT discussions, 
explaining why this attribute was considered less important 
in the final ranking.
Individual patient analyses revealed different  profiles 
of respondents (Table 4). Some patients (prof ile 1) 
did not change their ranking after discussion, some 
(profile 2) made minor changes to some parameters, and 
others  (profiles 3–4) made more substantial changes in 
Table 2 Participants’ characteristics
Women n(%) 24/26 (92%)
Belgian n(%) 17/26 (66%)
Age (years)
 Mean, median, standard deviation 68.0, 67.0, 11.0
 Range 41–87
Diagnosis of osteoporosis 25 (96%)
Osteoporosis since (years)
 Mean, median, standard deviation 10.2, 8.0, 8.7
 Range 0–38
Education
 No, primary or low secondary 9 (37%)
 Secondary school 9 (37%)
 Graduate/University 6 (25%)
With prior fracture 15 (58%)
Number of prior fractures
 Mean, median, standard deviation 1.04, 1.00, 1.22
 Range 0–5
Patients on treatment 25 (96%)
Patients who took another treatment in the past 9 (35%)
Patients who experienced adverse events 4 (15%)
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their  ranking. After discussion, the average absolute 
change per patient between the ranking of the 12 attributes 
in the second ranking list compared with that in the first 
ranking list was 1.3 ± 0.8, meaning that on average each 
attribute moved (in absolute terms) by 1.3 places. The 
average number of attributes changed after discussion 
was 6.8 ± 3.1. As reported in Figure 2, the NGT discus-
sion had the lowest impact on the attributes ranked as 
the three most important in the initial ranking, while the 
attributes ranked in the fifth and sixth positions were the 
most affected by discussion.
Additional findings
First, 15% of patients (4/26) did not correctly rank from 1 
to 12 because they assigned the same number to different 
attributes. Second, the order of presentation of attributes in 
the rank system and nominal group discussion seemed to 
influence the ranking. When the attributes were presented 
in the first positions of the list, they generally obtained 
their highest score. Third, group analyses suggest that 
out-of-pocket cost was not in the top four in the two Dutch 
groups (fifth and eleventh position) reflecting the fact that, 
in contrast with Belgian patients (ranked as third, fifth 
and eighth), they have no out-of-pocket contribution for 
medications. No other major differences were observed 
between the groups. Finally, only one patient included 
a missing attribute, ie, drug interactions, which was dis-
cussed previously.
Selection of final attributes
Rankings and NGT discussions revealed four important 
attributes which were consistently identified as important for 
patients, ie, effectiveness, side effects, mode and frequency 
of administration. Interestingly, the finding that out-of-
pocket cost was considered important in Belgium, but not 
in The Netherlands, suggests that this attribute could only 
be included in countries like Belgium where it is relevant. 
For most patients, time on market was related to safety and 
fewer side effects, which were already included as attributes. 
Place of administration is highly correlated with mode of 
administration and should rather be incorporated in the 
description of mode of administration. Other attributes were 
not sufficiently important for inclusion in the DCE based on 
ranking and discussion. Based on these considerations, we 
decided to include the four first attributes for the DCE in 
The Netherlands and the fifth attribute (out-of-pocket cost) 
in Belgium only.
Table 3 Ranking of osteoporosis medication attributes before 
and after Nominal Group Technique meeting
Initial ranking Final ranking
Effectiveness  1 (2.0)  1 (1.6)
Side effects  2 (3.2)  2 (3.8)
Frequency of administration  3 (5.2)  3 (4.4)
Mode of administration  4 (5.4)  4 (5.8)
Out-of-pocket cost 10 (7.8)  5 (6.0)
Time on market  6 (6.0)  6 (6.4)
Place of administration  7 (6.6)  7 (6.6)
Mode of action  5 (5.8)  8 (6.8)
Sequential therapy  8 (7.2)  9 (7.0)
Mono or combination  9 (7.4) 10 (7.4)
Branded/generic 11 (8.8) 11 (9.0)
Cost for society 12 (11.6) 12 (11.8)
Note: The average ranks assigned to each attribute in the five groups are provided 
in parentheses.
0 1 2 3 4 5
Cost for society
Mode of action
Mono or combination
Branded/generic
Time on market
Place of administration
Sequential therapy
Out-of-pocket cost
Mode of administration
Frequency of administration
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in the five most important attributes
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3th
4th
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Figure 1 Most important attributes for medications used to treat osteoporosis.
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Discussion
We have demonstrated the feasibility of the NGT in prioritiz-
ing attributes for inclusion in DCEs. When many candidate 
attributes are identified from available sources or patient 
interviews, this approach may be beneficial for assessing the 
importance of these attributes to construct the DCE. Therefore, 
in situations where the number of attributes identified needs 
to be restricted, a two-stage analysis could be performed, in 
which a self-exploratory analysis reduces the number of attri-
butes (using NGT for example) and a DCE is conducted with 
the restricted list of attributes to assess further preferences for 
the levels of the attributes. Other tools (eg, best-worst scal-
ing, adaptive conjoint analysis where attributes are changed 
simultaneously) could be alternative approaches.
Starting from a comprehensive list of attributes for 
osteoporosis medication generated from the literature and 
expert opinion, we identified which medication attributes are 
important from the patient perspective. Rankings and discus-
sion revealed four important attributes, ie, effectiveness, side 
effects, and mode and frequency of administration.
These results are interesting for designing DCE experi-
ments, and are also worthwhile in themselves when aiming 
to improve therapeutic adherence. Poor adherence with 
osteoporosis medication is a well documented problem,20 
which results in significant clinical and economic burden.21,22 
Barriers to adherence include side effects, inconvenient dos-
ing regimens, lack of information, and cost of medication.23 
Providing patients with adequate information on the treat-
ment options and involving them in decision-making may 
contribute to optimizing selection of treatment and improving 
adherence to therapy.24,25 Because drug therapies in osteopo-
rosis differ in their side effect profiles as well as mode and 
Table 4 Different profiles of responders after NGT discussiona
Number of 
patients
Average absolute change 
between attributes’ rankings: 
mean (standard deviation)b
Number of attributes 
changed: mean 
(standard deviation)
Profile 1 (0) 5 0 (0) 0 (0)
Profile 2 (.0–1) 6 0.85 (0.13) 6.7 (1.4)
Profile 3 (.1–2) 9 1.76 (0.13) 8.5 (0.7)
Profile 4 (.3) 5 2.58 (0.27) 10.8 (1.4)
Notes: aProfiles of responders were determined based on the average absolute change between attributes’ rankings. Profiles’ classification is provided in parentheses in the 
first column; bthe average absolute change between attributes’ rankings was obtained by summing, for each attribute, the absolute change between initial and final ranking 
(a positive change (+1) or a negative change (-1) are treated the same (+1)) and dividing by the number of attributes.
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Figure 2 Mean absolute change in ranking of attributes after NGT discussion according to their rank in the initial round.
Note: Graph shows that the attributes in the first three positions (that differ according to individual patient’s ranking) are the most stable after NGT discussions.
Abbreviation: NGT, nominal group technique.
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frequency of administration, and these were considered to be 
important attributes in our research, sharing this information 
with patients could lead to optimized selection of treatment 
and improved adherence with therapy.
In the context of this study, the NGT discussions did not 
substantially affect rank order of preferences for the attributes 
in the total group when compared with rank order before the 
NGT discussion, indicating considerable agreement for the 
most important attributes. This suggests that a simple ranking 
exercise (or best-worst scaling) may perhaps be sufficient 
to determine the most important attributes. However, indi-
vidual analyses have suggested that 80% of patients changed 
their ranking after discussion, and this could potentially be 
reflected in a different group ranking. Therefore, further 
investigations in other contexts, other diseases, and other 
decisional issues are needed to determine the added value of 
the NGT meeting when selecting and prioritizing attributes 
for a DCE or even other purposes.
The approach described here also has the advantage of 
being rigorous, systematic, and transparent, and so may 
improve the face validity of DCEs. Many papers have pointed 
out that conjoint analysis did not justify the selection of 
attributes very well.5,19,26 Recently, Coast et al explored issues 
associated with attribute development for DCEs, and con-
trasted different qualitative approaches in the development 
of DCEs based on experience generated in interviews.5 Our 
study generated further insight by providing additional expe-
rience from group discussions. The benefits of conducting 
qualitative research were also not restricted to the selection 
of attributes. Discussions have been interesting in terms of 
refining language5 and for conducting a Bayesian efficient 
design.27 However, application of such a method did not 
come without a cost. We estimate that the whole process 
of organizing, running, and analyzing the NGT cost about 
€10,000 (including about €1500 as an incentive to patients 
for time spent and 2–3 months of the services of a full-time 
researcher). However, we believe that the benefits of the 
approach make it highly cost-effective.
The NGT could also be useful in selecting the initial set 
of attributes. Participants could first be asked individually 
to generate a list of important medication attributes, fol-
lowed by discussion refining the list by adding, merging, or 
removing attributes, and by the final individual ranking of 
the most important attributes. This was not done in our study 
because many potential attributes were already identified by 
the literature review and we also aimed to assess the impact 
of the NGT session on rank order. However, our patients had 
the opportunity to add attributes to the list. Our study could 
also have some important implications for further research 
in this area. First, misunderstanding of attributes is frequent, 
and a clear description and explanation of the attributes is 
required. Second, ranking many attributes could impose a 
substantial cognitive burden on respondents. Perhaps it would 
have been sufficient to ask patients to rank their five most 
important attributes. Rating scales per attribute could also be 
an alternative requiring less effort on the respondent’s part, 
but with more limited information on the relative importance 
of attributes. Further work should be done to assess and 
compare ranking/rating exercises. Third, the impact of the 
NGT discussion was shown to differ substantially between 
patients. It would be interesting in the future to identify rea-
sons that could explain this. Finally, our study showed that 
the presenting order of attributes did have an impact on the 
results. Therefore, we recommend controlling for ordering 
effects in ranking exercises.
A limitation of this study is that we have not compared 
the attributes derived from NGT with other approaches (eg, 
expert opinion, best-worst scaling). The gold standard would 
be the preference revealed, but this outcome is also difficult 
to assess. Head-to-head comparisons of different techniques 
could help to assess and understand differences between 
approaches, although there may be practical limitations in 
developing such studies.5
Conclusion
A nominal group technique is feasible for selecting attri-
butes for DCEs. Although, in the context of this study, the 
NGT discussions did not substantially affect the patients’ 
rank order of preferences for the attributes when compared 
with rank order before the group discussion, our approach 
is rigorous, transparent, and improves the face validity of 
future DCEs. Further work should be done to determine 
the added value of the NGT session, to assess the optimal 
ranking/rating method with control of ordering effects, 
and to compare the attributes selected using the different 
approaches.
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